<DOC>
	<DOCNO>NCT01822340</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability Pharmacokinetic/ Pharmacodynamic ( PK/PD ) profile three dos HM10560A every week ( EW ) regime one dose every week ( EOW ) regime administer period 24 week initial study .</brief_summary>
	<brief_title>Safety Efficacy Study Recombinant Human Growth Hormone Adult Growth Hormone Deficiency Patients</brief_title>
	<detailed_description>- To select optimal dose dose regimen HM10560A subsequent phase III study basis safety PK/PD profile 24 week treatment - To assess long term safety HM10560A administer optimal dose range dose frequency additional 48 week ( follow 2 week safety follow )</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>GHDA subject , male female , age 23 60 year define Consensus Guidelines Diagnosis Treatment Adults GH Deficiency II ( 2007 ) well American Association Clinical Endocrinologists Medical Guidelines Clinical Practice Growth Hormone Use Growth HormoneDeficient Adults Transition Patients ( 2009 ) ; rhGHdrug na√Øve register investigational rhGH replacement therapy give 6 month screen . Body Mass Index ( BMI , kg/m2 ) male female patient must 22.0 35.0 kg/m2 . Female patient must negative serum pregnancy test inclusion . Confirmed negative anti rhGH antibody time screen . Willing able provide write informed consent prior perform study procedure . Patients childhood onset GHD treat rhGH age 18 . Current antitumor therapy . Subjects present clinically significant ECG abnormality . Evidence intracranial hypertension . Significant hepatic dysfunction ( persistent elevation alanine transaminase [ ALT ] aspartate transaminase [ AST ] &gt; 1.5 x upper limit normal ) . Pregnancy breastfeeding ;</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>AGHD</keyword>
</DOC>